PepGen (PEPG)
Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.
Something off on this page? Send us feedback.
Develops peptide-enabled oligonucleotide therapies for serious genetic neuromuscular and neurological diseases. Its active clinical focus is PGN-EDODM1 for myotonic dystrophy type 1, with no approved products or product-sales revenue.
Develops peptide-enabled oligonucleotide therapies for serious genetic neuromuscular and neurological diseases. The EDO platform pairs proprietary peptides with oligonucleotides to improve cellular uptake and nuclear delivery.
PGN-EDODM1, for myotonic dystrophy type 1, is the active clinical focus after development of the DMD candidate PGN-EDO51 ceased. The delivery technology originated in research at the University of Oxford and the MRC Laboratory of Molecular Biology.
Founded to develop the licensed delivery approach created from this research, the organization has no approved products or product-sales revenue. The FREEDOM2 trial is subject to an FDA partial hold tied to previously submitted preclinical pharmacology and toxicology studies, while sites outside the United States remained active. Research and clinical development define the operating model.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 13, 2026 | Wedbush | Reiterate | Rating: —Target: $9 | Target: $4 |
| Feb 18, 2026 | Guggenheim | Reiterate | Rating: —Target: — | Target: $7 |
| Oct 28, 2025 | H.C. Wainwright | Target | Target: $26 | Target: $18 |
| Sep 25, 2025 | Stifel Nicolaus | Target | Target: — | Target: $12 |
| Sep 25, 2025 | Wedbush | Reiterate | Rating: —Target: — | Target: $9 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $117.2M · Total debt $16.1M · Total assets $141.4M · Shareholders' equity $119.5M
- Revenue
- $0
- Operating income
- −$18.9M
- Net income
- −$17.8M
No dividends on record.
| Institutions | 75.17% | 52.06M shares | |
|---|---|---|---|
| 74 holders · as of Jun 30, 2026 | |||
| Insiders | 0.89% | 614.9K shares | |
| 6 holders · as of May 26, 2026 | |||
| Strategic holders | 7.15% | 4.96M shares | |
| 1 holder · as of Oct 1, 2025 | |||
| Other | 16.79% | 11.63M shares | |
| remainder | |||
69.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Ra Capital Management, L.P.Institution | 28.97% | 20.06M | as of Jun 30, 2026 |
Oxford Science Enterprises plcStrategicother: Former 10% Owner | 7.15% | 4.96M | filed Oct 1, 2025 |
Commodore Capital LPInstitution | 6.46% | 4.48M | as of Jun 30, 2026 |
Viking Global Investors LPInstitution | 5.03% | 3.48M | as of Jun 30, 2026 |
Laurion Capital Management LPInstitution | 3.97% | 2.75M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Kasra Kasraian | officer: Chief Technical Officer | −1,233 | $1.41 |
| Mar 4, 2026 | James G. McArthur | director, officer: President and CEO | −5,275 | $6.23 |
| Mar 4, 2026 | Noel Donnelly | officer: Chief Financial Officer | −2,084 | $6.23 |
| Mar 4, 2026 | Paul Streck | officer: EVP, Head of R&D | −1,879 | $6.23 |
| Sep 30, 2025 | Oxford Science Enterprises plc | other: Former 10% Owner | +200,000 | $3.20 |
- Novartis (ADR)
DMPK-targeting siRNA therapy in Phase 3 DM1 testing
- Dyne Therapeutics
DMPK-targeting Fab-ASO program in registrational DM1 development
- Vertex Pharmaceuticals
Peptide-linked oligonucleotide therapy in Phase 1/2 DM1 testing
- Arrowhead Pharmaceuticals
RNAi therapy in Phase 1/2 development for DM1
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PepGen | $2.77 | −6.92% | $206.1M | — | — | — | — |
| Novartis (ADR) | $142.50 | +0.86% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| Dyne Therapeutics | $16.58 | −3.27% | $3.20B | — | — | — | — |
| Vertex Pharmaceuticals | $514.52 | −0.09% | $130.71B | 30.0 | 26.8 | 10.4 | +12.5% |
| Arrowhead Pharmaceuticals | $68.45 | −4.75% | $10.12B | — | — | 15.1 | +171.0% |
| Median | 25.6 | 21.0 | 10.4 | +12.5% |